LAS VEGAS, NV, BASKING RIDGE, NJ, and TOTOWA, NJ — From the 2012 International Consumer Electronics Show (CES), Verizon Wireless and VectraCor, Inc. today said the Vectraplex Holter System is being shown at the Verizon booth (Las Vegas Convention Center, South Hall, Booth #30259).
The Vectraplex Holter System is an ambulatory cardiac monitor that incorporates an electrocardiogram (ECG) amplifier and a cell module using Verizon Wireless service. Currently under development, the Vectraplex Holter will use the “Cardiac Electrical Biomarker,” VectraplexAMI, which received FDA approval in November 2011, on VectraCor’s VectraplexECG System. This technology will detect ECG changes indicative of an acute myocardial infarction (AMI, heart attack), non-invasively and in real time, and display a derived 15 lead ECG from the acquisition of 3 leads (5 electrodes). For the first time, a patient can be anywhere on the Verizon Wireless network and the Vectraplex Holter System will automatically send an email over the network to the physician when the patient is having ECG changes indicative of an AMI or other events, allowing the physician to review the derived 15 lead ECG. The device will also send data on patient-initiated events.
Cardiovascular disease is the No. 1 killer in the world, and the need to improve the detection and monitoring of a heart attack is crucial. The current emergency room practice of chest pain evaluation is to connect the patient to a cardiac monitor (3-5 electrodes), then connect an additional 12 lead ECG machine (additional 10 electrodes), and then draw blood to measure serum biomarkers, repeated approximately every three to six hours during an 18- to 24-hour-period.
The Vectraplex Holter System is an ambulatory cardiac monitor that patients can wear at home or in the hospital to detect ECG changes suggestive of an AMI within seconds and derive the 15 lead ECG (12 lead and vectorcardiogram XYZ leads, including VCG loops) from the acquisition of only 3 leads (5 electrodes). VectraCor’s disruptive technology is patented worldwide and will provide valuable clinical information to both patients and clinicians.
Brad S. Schreck, president and chief executive officer for VectraCor, said, “VectraCor is very pleased to work with Verizon Wireless, enabling our disruptive technology to help patients with cardiovascular disease, the No. 1 killer in the world. We expect to submit the 510k to the FDA in the first quarter of 2012 for this new product.”
Verizon established its Innovation Program to encourage collaboration and help advance the 4G LTE ecosystem. The company’s LTE Innovation Center in Waltham, Mass., and its Application Innovation Center in San Francisco were created to inspire, enable and develop non-traditional devices, services and applications that take advantage of Verizon Wireless’ industry-leading wireless networks. Through the Innovation Program, Verizon seeks to expand the possibilities of 4G LTE by working with diverse companies, from start-ups to established players, in industries representing a broad range of verticals.
(EDITOR’S NOTE: Media attending CES 2012 in Las Vegas can visit Verizon Wireless and VectraCor at LVCC, South Hall, Booth #30259.)
About Verizon WirelessVerizon Wireless operates the nation’s largest 4G LTE network and largest, most reliable 3G network. The company serves 107.7 million total wireless connections, including 90.7 million retail customers. Headquartered in Basking Ridge, N.J., with nearly 83,000 employees nationwide, Verizon Wireless is a joint venture of Verizon Communications (NYSE, NASDAQ: VZ) and Vodafone (LSE, NASDAQ: VOD). For more information, visit www.verizonwireless.com. To preview and request broadcast-quality video footage and high-resolution stills of Verizon Wireless operations, log on to the Verizon Wireless Multimedia Library at www.verizonwireless.com/multimedia.
About VectraCor, Inc.VectraCor is a medical device company in Totowa, NJ with disruptive patented technology in the cardiovascular market place. Cardiovascular disease is the #1 disease and killer in the US and World. VectraCor’s technology has the potential to be the new standard of care in cardiac monitoring. For more information please visit VectraCor at www.vectracor.com or contact Brad S. Schreck at 973-768-0402 or email firstname.lastname@example.org.